CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab

BACKGROUND: The mammalian target of rapamycin (mTOR) signaling pathway plays a pivotal role in numerous cellular processes involving growth, proliferation and survival. The purpose of this study was to investigate the anti-tumoral effect of the mTOR inhibitor (mTORi) CCI-779 in HNSCC cell lines and...

Descripción completa

Detalles Bibliográficos
Autores principales: Niehr, Franziska, Weichert, Wilko, Stenzinger, Albrecht, Budach, Volker, Tinhofer, Ingeborg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389307/
https://www.ncbi.nlm.nih.gov/pubmed/25890004
http://dx.doi.org/10.1186/s12967-015-0456-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389307/
https://www.ncbi.nlm.nih.gov/pubmed/25890004
http://dx.doi.org/10.1186/s12967-015-0456-6

Ejemplares similares